Report #2856835

Received Sep 4, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Unknown
Age: Age unknown
State: TX
Recovered: Unknown
Vaccinated: Aug 11, 2025
Onset: Aug 11, 2025
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
MENB	MENINGOCOCCAL B (BEXSERO)	NOVARTIS VACCINES AND DIAGNOSTICS	2	UNK	—

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

Bexsero early second dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too short in a patient who received Men B NVS (Bexsero) for prophylaxis. Concomitant products included MENINGOCOCCAL VACCINE B RFHBP/NADA/NHBA OMV (BEXSERO). On 11-AUG-2025, the patient received the 2nd dose of Bexsero. On 11-AUG-2025, an unknown time after receiving Bexsero, the patient experienced drug dose administration interval too short (Verbatim: Bexsero early second dose). The outcome of the drug dose administration interval too short was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 14-AUG-2025 The reporter reported that the clinics gave the second Bexsero dose too soon and first dose was given on May 2025 and then second dose on Monday which led to drug dose administration interval too short. The reporter asked if they should give a third dose, or it was okay.

Other medications

BEXSERO